• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RadNet Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    9/12/24 4:41:43 PM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email
    RadNet, Inc. 8-K
    false 0000790526 0000790526 2024-09-11 2024-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) September 11, 2024

     

    RadNet, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33307   13-3326724
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer Identification No.)

     

    1510 Cotner Avenue    
    Los Angeles, California   90025
    (Address of Principal Executive Offices)   (Zip Code)

      

    (310) 478-7808

    Registrant’s Telephone Number, Including Area Code

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.0001 par value RDNT NASDAQ Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On September 11, 2024 RadNet, Inc. (“RadNet”) appointed Cornelis “Kees” Wesdorp, age 47, to serve as President and Chief Executive Officer of its Digital Health segment (“Digital Health”), which includes RadNet’s eRad and Artificial Intelligence businesses, effective October 1, 2024.

     

    Prior to joining RadNet, Mr. Wesdorp served as a Managing Director of the private equity firm Hellman & Friedman in London, where he co-led the EU Operations group since February 2023. From 2017 to 2022 Mr. Wesdorp was an executive with Phillips Group in Amsterdam, starting as an executive vice president overseeing the Diagnostic Imaging businesses before being promoted in 2020 to Phillip’s executive committee with responsibility for overseeing the multi-billion euro Precision Diagnosis Division, focused on diagnostic imaging solutions for health systems including imaging systems, informatics and artificial intelligence. From 2011 to 2016, Mr. Wesdorp was an executive vice president with the private equity firm Bain Capital in London, performing various operating partner roles for portfolio companies. From 2006 to 2011, he served in various management roles with NXP Semiconductor, a semiconductor manufacturing and design company based in Eindhoven, Netherlands. Mr. Wesdorp began his career at McKinsey & Company in Amsterdam. Mr. Wesdorp earned a Masters Degree in Physics from the University of Amsterdam and a PhD in Experimental Atomic Physics from Vrije University in Amsterdam.

     

    On September 11, 2024, Mr. Wesdorp entered into an employment agreement (the “Employment Agreement”) with Aidence B.V., a wholly owned subsidiary of RadNet, which provides that he will serve as a director of Aidence B.V. and as President and Chief Executive Officer of RadNet Digital Health. Mr. Wesdorp will be based in the Netherlands. The employment term will start October 1, 2024, and will continue until terminated by either RadNet or Mr. Wesdorp.

     

    Under the Employment Agreement, Mr. Wesdorp will receive (a) an annual base salary of €636,000, (b) reimbursement for a family medical insurance premium, (c) five weeks (twenty-five days) of vacation per year, and (d) reimbursement of all reasonably incurred business expenses. Mr. Wesdorp will also receive a bonus equal to his annual compensation in both 2026 and 2027, payable on the date that RadNet pays bonuses to its executive officers for that year, provided that (i) the employment agreement remains in effect on such payment date and (ii) Mr. Wesdorp has not been sick or incapacitated for more than an aggregate of thirty calendar days during the twelve months immediately preceding such payment date. The bonus is payable, at the discretion of RadNet’s Compensation Committee, in cash or shares of RadNet’s common stock.

     

    The Employment Agreement contains commercially standard covenants regarding the protection of confidential information and intellectual property rights, as well as restrictions against Mr. Wesdorp competing against RadNet or soliciting its employees during the term of the agreement and for a period of twelve months following its termination. The Employment Agreement also contains provisions regarding, among other things, governing law, dispute resolutions and covenants governing Employee’s conduct. The foregoing summary of the Employment Agreement is not intended to be complete and is qualified in its entirety by reference to the copy of the Employment Agreement attached as Exhibit 10.1 to this report.

     

    In connection with the entry into the Employment Agreement, RadNet has agreed to provide Mr. Wesdorp with a signing bonus of $750,000 payable in shares of RadNet common stock (valued on the commencement of employment) and to grant Mr. Wesdorp restricted stock units for 50,000 shares of RadNet common stock, which will vest in equal 10,000 share increments on each of the succeeding five anniversaries of the commencement of employment. The equity awards will be issued pursuant to RadNet’s Equity Incentive Plan.

     

    On September 12, 2024, RadNet issued a press release announcing the appointment of Mr. Wesdorp, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01.Financial Statements and Exhibits.

     

    (d)Exhibits

     

    Exhibit
    Number
      Description

    10.1

     

      Employment Agreement, dated September 11, 2024, between Aidence B.V. and Cornelis Wesdorp
    99.1 Press Release dated September 12, 2024.
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      RadNet,  Inc.
       
       
      By: /s/ David J. Katz
        David J. Katz
        Executive Vice President, Chief Legal Officer and UK Executive Sponsor
         
    Date: September 12, 2024    

     

     

     

     

     

     

     

     

     

     

     3 

    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP of Fin Planning, CAO Patel Mital was granted 20,667 shares, increasing direct ownership by 12% to 200,175 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:14 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Pres & CEO, Digital Health Wesdorp Cornelis was granted 20,330 shares, increasing direct ownership by 38% to 73,825 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:10 PM ET
    $RDNT
    Medical Specialities
    Health Care

    EVP and Chief Legal Officer Katz David Jeffrey was granted 19,289 shares, increasing direct ownership by 27% to 90,866 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:12 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    SEC Filings

    View All

    SEC Form 10-K filed by RadNet Inc.

    10-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 5:17:51 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 7:01:44 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 7:00:48 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DeepHealth Unveils Industry's Most Comprehensive Portfolio of Native Clinical AI Solutions at ECR 2026

    VIENNA, March 04, 2026 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities — MR, CT, X-ray, Mammography and Ultrasound — and spanning detection, assessment and monitoring, all available on one platform. With this week's acquisition of Gleamer, DeepHealth further expands its leadership in advancing screening tools into routine imaging and acute diagnostic care, uniquely positioned to deliver the next era of AI-powered health informatics.  "As European na

    3/4/26 7:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Butterfly Network (NYSE:BFLY), Tempus AI (NASDAQ:TEM), RadNet (NASDAQ:RDNT), and GE HealthCare (NASDAQ:GEHC) are conv

    3/3/26 12:19:00 PM ET
    $BFLY
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Computer Software: Programming Data Processing

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

    Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of

    3/2/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Acquires Gleamer, Making RadNet's DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide

    Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications.Gleamer's leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer's solutions will provide the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities. Gleamer achieved an Annual Recurring Revenue ("ARR") i compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 millio

    3/2/26 5:45:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care